Byron L. Lam
Expertise in
35
conditions

Dr. Byron L. Lam

Ophthalmology
900 Northwest 17th Street, 
Miami, FL 
Accepting New Patients
Offers Telehealth
Expertise in
35
conditions
900 Northwest 17th Street, 
Miami, FL 

Overview

Byron Lam is an Ophthalmologist practicing medicine in Miami, Florida.

Dr. Lam is highly rated in 35 conditions, according to our data. His clinical expertise encompasses X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Optic Nerve Atrophy, Vitrectomy, and Nerve Decompression.

He is actively involved in clinical research, co-authoring 208 peer reviewed articles and participating in 16 clinical trials. Dr. Lam is currently accepting new patients.

Graduate Institution

Boston University School Of Medicine - 1986

Residency

University of Iowa Hospital & Clinics, Ophthalmology - 1990

Specialties

Ophthalmology

Licenses

Ophthalmology in FL

Fellowships

Bascom Palmer Eye Institute, Neuro-Ophthalmology - 1991
Illinois Eye and Ear Infirmary, UIC, Retina/Vitreous - 1992

Hospital Affiliations

Doctors Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Guardian Life Insurance Company
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

900 Northwest 17th Street, Miami, FL 33136

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Device
Study Phase: Not Applicable
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Injection of scAAV2-P1ND4v2
Study Phase: Phase 1
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Drug, Other
Study Drug: Ultevursen
Study Phase: Phase 2/Phase 3
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss
Enrollment Status: Terminated
Publish Date: June 16, 2022
Intervention Type: Drug, Procedure
Study Phase: Phase 3
Natural History Study of CEP290-Related Retinal Degeneration
Natural History Study of CEP290-Related Retinal Degeneration
Enrollment Status: Completed
Publish Date: May 19, 2022
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2022
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

207 Total Publications

Visual Impairment and Cardiovascular Risk Factors in Hispanic and Latino Adults.
Visual Impairment and Cardiovascular Risk Factors in Hispanic and Latino Adults.
Journal: JAMA network open
Published: June 12, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Harry W. Flynn
Ophthalmology
Expertise in
24
conditions
Dr. Harry W. Flynn
Ophthalmology
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harry Flynn is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Flynn is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Endophthalmitis, Retinal Detachment, Interstitial Keratitis, Vitrectomy, and Cataract Removal. Dr. Flynn is currently accepting new patients.

Expertise in
25
conditions
Dr. Janet L. Davis
Ophthalmology
Expertise in
25
conditions
Dr. Janet L. Davis
Ophthalmology
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
 (0.1 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Janet Davis is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Davis is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Uveitis, Birdshot Chorioretinopathy, Endophthalmitis, Vitrectomy, and Cataract Removal. Dr. Davis is currently accepting new patients.

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Philip Rosenfeld is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Rosenfeld is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Carotid Artery Surgery, and Vitrectomy. Dr. Rosenfeld is currently accepting new patients.

Frequently Asked Questions about Dr. Byron L. Lam

Is Dr. Byron L. Lam a top-rated expert for X-Linked Retinitis Pigmentosa (XLRP)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Byron L. Lam is classified as an Elite expert for X-Linked Retinitis Pigmentosa (XLRP), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Byron L. Lam specialize in?

While Dr. Byron L. Lam is a Ophthalmology, they have specific expertise in X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, and Optic Nerve Atrophy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Ophthalmology.

Does Dr. Byron L. Lam participate in research or clinical trials?

Yes. Dr. Byron L. Lam has published 207 articles and abstracts on conditions like X-Linked Retinitis Pigmentosa (XLRP). You can view a list of Dr. Byron L. Lam's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Byron L. Lam accept my insurance?

Dr. Byron L. Lam accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lam's expertise for a condition
ConditionClose
View All 17 Distinguished Conditions
View All 12 Advanced Conditions
View All 44 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile